Biopharmaceuticals and Protein Analysis

Multi-isocratic elution mode is a powerful chromatographic approach for characterizing minor isoforms of monoclonal antibodies.

Flow-through immobilized-enzyme reactors (IMERs) can streamline protein digestion for bottom- and middle-up LC–MS characterization while providing high accuracy and reproducibility.

Commercially available trypsin IMERs can digest proteins with high sequence coverage and robustness, facilitating online multidimensional LC–MS.

Leading biopharmaceutical companies are integrating HPLC into production processes for monitoring critical quality attributes (CQAs) with high-resolution mass spectrometry (HRMS) detection.

This work compares at-line Protein A-MS with a standard multi-attribute method (MAM) workflow for analyzing product quality attributes (PQAs) during upstream processing.

High-resolution mass spectrometry (HRMS) is an increasingly critical tool for identifying, characterizing, and monitoring attributes of protein-based therapeutics.

If we are going to achieve widespread adoption of multidimensional separations, we need more systematic approaches to method development that rely less on user experience.

Charge detection mass spectrometry (CDMS) is a useful tool to characterize larger, more complex biopharmaceuticals like bispecific antibodies and ADCs.

Barry L. Karger and James P. Grinias are the winners of the 15th annual LCGC Lifetime Achievement and Emerging Leader in Chromatography Awards, respectively, for 2022. Here, we review their achievements.

We review different approaches and coupling strategies for analyzing monoclonal antibody aggregates with 2D-LC.

Intact mass analysis is becoming increasingly useful for characterizing biologics. We describe the current application of intact mass analysis, including quantitation, sequencing, and structural characterization.

Recent developments in high-resolution mass spectrometry (HRMS) are aiding biopharmaceutical development and simplifying routine monitoring, with applications in areas like multi-attribute methods, coupling established purity methods with MS, and subunit analysis.

A validated FFF-MALS method aligned with technical specification ISO/TS 21362 for the analysis of lipid-based nanoparticles (LNPs) encapsulating siRNA and mRNA is presented.

There is a need to use more descriptive and precise terms to describe some of the properties of the products used for biopharmaceutical analysis. It is probably more correct to say “low adsorption” and “corrosion-resistant” systems.

We present the main analytical techniques for performing functional characterization of biotherapeutic products. Such assessments are particularly critical for biosimilars, where analytical testing must ensure functional comparability with the innovator product.

We explore the impact of two different stationary phases and ion-pair reagents on the retention behavior of a therapeutic peptide using reversed-phase liquid chromatography. This information is of fundamental importance for the development of reliable, selective, and fast analytical methods able to separate and identify the target peptide.

The benefits of a robustness assessment for the analysis of a NIST mAb using a wide pore C4 LC column are described.

In the second part of this review of the current state of HIC, some practical considerations are explained, including method development, selection of the phase system, combined salt systems, and possibilities to combine HIC with other chromatographic modes.

A review of the current state of HIC, focusing on retention and separation mechanisms with the aim of developing more robust methods. Can HIC be considered as a non-denaturing and non-destructive technique with advantages for protein analysis?

Recent advances in stationary phases for hydrophobic interaction chromatography (HIC) permit HIC–MS analysis of intact antibodies and other proteins using direct flow to the mass spectrometer.

New analytical workflows are needed to address the advances in biopharmaceutical product composition. A description of the multi-attribute method (MAM) is given, which has been developed to monitor critical quality attributes (CQAs) simultaneously and directly.

Recombinant adeno-associated viral therapy (rAAV) products are particularly complex. Are liquid chromatography and LC–MS the right tools for their characterization?

IMS is a valuable tool for biopharmaceutical analysis. Two formats in particular have proven useful: cyclic IMS and structures for lossless manipulations (SLIM).

This article explores the potential of microchip capillary electrophoresis–mass spectrometry (CE–MS) for the characterization of intact biopharmaceuticals, and how this technique can effectively be employed to monitor essential quality attributes of interest.